School of Medicine, Deakin University, Geelong, 3220, Australia.
Purinergic Signal. 2022 Dec;18(4):387-393. doi: 10.1007/s11302-022-09865-3. Epub 2022 Apr 26.
Kidney transplantation is the preferred treatment for individuals with kidney failure offering improved quality and quantity of life. Despite significant advancements in short term graft survival, longer term survival rates have not improved greatly mediated in large by chronic antibody mediated rejection. Strategies to reduce the donor kidney antigenic load may translate to improved transplant survival. CD39 on the vascular endothelium and on circulating cells, in particular regulatory T cells (Treg), is upregulated in response to hypoxic stimuli and plays a critical role in regulating the immune response removing proinflammatory ATP and generating anti-inflammatory adenosine. Herein, the role of CD39 in reducing ischaemia-reperfusion injury (IRI) and on Treg within the context of kidney transplantation is reviewed.
肾移植是治疗肾衰竭患者的首选方法，可提高生活质量和数量。尽管短期移植物存活率有了显著提高，但长期存活率并没有得到很大改善，这在很大程度上是由于慢性抗体介导的排斥反应所致。减少供体肾脏抗原负荷的策略可能会转化为改善移植的存活率。血管内皮细胞和循环细胞（特别是调节性 T 细胞[Treg]）上的 CD39 在受到缺氧刺激时上调，在调节免疫反应中发挥着关键作用，可去除促炎的三磷酸腺苷（ATP）并生成抗炎的腺苷。本文综述了 CD39 在肾移植中减轻缺血再灌注损伤（IRI）和 Treg 中的作用。
